Medical Condition News

RSS

Entelos awarded U.S. patent for apparatus and methods of assessing metabolic substrate utilization

Entelos, Inc., a simulation and modeling company focused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled “Apparatus and Methods for Assessing Metabolic Substrate Utilization” to the Company. These methods further strengthen the Entelos® Metabolism PhysioLab® platform and leverage insights about human physiology that can lead to improved diagnosis, clinical testing, and personalized treatment across a highly variable patient population.

2 Feb 2010

Women's metabolic disorder remains largely undiagnosed

Gail Donnelly's classmates nicknamed her "Knobby" because she was so skinny all her bones seemed to poke out from under her skin. But when Donnelly turned 27, that once knobby frame disappeared under mysteriously ballooning weight.

2 Feb 2010

Researchers discover new mechanism to burn body fat

Researchers reporting in the February 3rd issue of Cell Metabolism may have a new way to trick the body into consuming more energy. The target in this case is an enzyme that indirectly controls the activity of what the researchers refer to as the "energy master switch." It boils down to this:

2 Feb 2010

GenSpera’s G-115 anti-cancer drug awarded US patent

GenSpera, Inc. announced that its patent application, entitled “Tumor Activated Prodrugs,” has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,635,682. The patent covers the composition and potential uses of G-115, GenSpera’s second anti-cancer drug in development.

2 Feb 2010

Research offers new hope for rare metabolic disorder

A research team led by biochemist Scott Garman at the University of Massachusetts Amherst has for the first time determined the mechanism of one of the cell's "recycling" enzymes, human alpha-galactosidase or alpha-GAL, as it breaks down substances in the lysosome, the cell's recycling center.

2 Feb 2010

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

2 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person's ability to straighten and properly use their fingers.

2 Feb 2010

FDA approves Taro Pharmaceutical Industries' levetiracetam tablets ANDA

Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Levetiracetam Tablets, 250 mg, 500 mg, 750 mg and 1000 mg (“levetiracetam tablets”).

2 Feb 2010

Persons with impaired hearing should be encouraged by family members to seek appropriate treatment

Recent data arising out of the Better Hearing Institute's "MarkeTrak" national study demonstrates that hearing loss is prevalent, serious, and often denied by the sufferer. The information revealed suggests that family members of the hearing impaired should actively encourage their loved ones to address their hearing problem, an effort which will greatly benefit both the hard of hearing and their kin.

2 Feb 2010

CTS: More people are being admitted to Canadian hospitals each year with COPD

A review of Canadian data by the nation's leading lung specialists has provided the factual evidence to support what respirologists across the country have been suspecting for some time. Shockingly, more people are being admitted to Canadian hospitals each year with chronic obstructive pulmonary disease (COPD) than any other major chronic illness (including heart attacks) and that number has been increasing dramatically in recent years.

2 Feb 2010

BC Cancer Foundation's campaign passes significant threshold with major donation for cancer care

Join the BC Cancer Foundation and community leaders for an exciting announcement which will significantly impact the lives of cancer patients and their families throughout Vancouver Island, the Gulf Islands and beyond.

2 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on ALL

Treating acute lymphocytic leukemia (ALL) can bring many challenges, particularly in the adult population. To optimally manage this disease in adult patients, healthcare professionals must understand and identify characteristics of high-risk disease, utilize best strategies for preventing central nervous system relapse, and recognize the important role of post-remission hematopoietic stem cell transplantation in ALL therapy.

2 Feb 2010

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.

2 Feb 2010

Health and environmental groups propose new ozone standard to help reduce asthma attacks and premature deaths

The American Lung Association, Breathe California, Coalition for Clean Air, Environmental Defense Fund and the Sierra Club will hold a joint press conference in support of the U.S. Environmental Protection Agency (EPA) proposal to strengthen the national limits for ozone "smog" pollution. The organizations are calling on the EPA to enact the most protective ozone standard under consideration to protect the health of our communities and the environment from serious harm.

2 Feb 2010

Researchers explore how brain circuitry and learning changes over time

New research shows our brains are a lot more chaotic than previously thought, and that this might be a good thing. Neurobiologists at the University of Maryland have discovered information about how the brain processes sound that challenges previous understandings of the auditory cortex, which had suggested an organization based on precise neuronal maps.

2 Feb 2010

Simulation training may help improve driving skills of Parkinson's disease patients

In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.

2 Feb 2010

New approach may help in fighting Cerebral Palsy

On average, a child is diagnosed with Cerebral Palsy every hour of every day in the United States. It's a disease that can affect everything from a child's vision to their ability to walk. Therapy for these kids is tough and frustrating as this is a chronic health condition.

2 Feb 2010

Study compares common treatment options for infants born with clubfoot

Clubfoot affects one in a thousand babies born in the United States, but with proper corrective treatment and follow-up, infants born with clubfoot can have feet compatible with an active, normal lifestyle. A new study in the February 2010 issue of the Journal of Bone and Joint Surgery (JBJS) compared two common treatment options for clubfoot - Ponseti method and surgical treatment.

2 Feb 2010